Cargando…

Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications

SIMPLE SUMMARY: Early-stage disease non-small cell lung cancer has better outcomes than advanced disease, but 5-year survival rates can drop to approximately 50% in cases of increased tumor size, local extension, or nodal spread. The use of liquid biopsies to enhance diagnosis, optimize perioperativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandekerckhove, Olivia, Cuppens, Kristof, Pat, Karin, Du Pont, Bert, Froyen, Guy, Maes, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216452/
https://www.ncbi.nlm.nih.gov/pubmed/37345038
http://dx.doi.org/10.3390/cancers15102702
_version_ 1785048301641400320
author Vandekerckhove, Olivia
Cuppens, Kristof
Pat, Karin
Du Pont, Bert
Froyen, Guy
Maes, Brigitte
author_facet Vandekerckhove, Olivia
Cuppens, Kristof
Pat, Karin
Du Pont, Bert
Froyen, Guy
Maes, Brigitte
author_sort Vandekerckhove, Olivia
collection PubMed
description SIMPLE SUMMARY: Early-stage disease non-small cell lung cancer has better outcomes than advanced disease, but 5-year survival rates can drop to approximately 50% in cases of increased tumor size, local extension, or nodal spread. The use of liquid biopsies to enhance diagnosis, optimize perioperative systemic treatments, and allow early detection of relapse is a possible strategy to reduce this burden. This review aims to present the current evidence on clinical applications of liquid biopsies in early-stage non-small cell lung cancer and highlight opportunities for future applications. ABSTRACT: Lung cancer remains the leading cause of cancer death worldwide, with the majority of cases diagnosed in an advanced stage. Early-stage disease non-small cell lung cancer (NSCLC) has a better outcome, nevertheless the 5-year survival rates drop from 60% for stage IIA to 36% for stage IIIA disease. Early detection and optimized perioperative systemic treatment are frontrunner strategies to reduce this burden. The rapid advancements in molecular diagnostics as well as the growing availability of targeted therapies call for the most efficient detection of actionable biomarkers. Liquid biopsies have already proven their added value in the management of advanced NSCLC but can also optimize patient care in early-stage NSCLC. In addition to having known diagnostic benefits of speed, accessibility, and enhanced biomarker detection compared to tissue biopsy, liquid biopsy could be implemented for screening, diagnostic, and prognostic purposes. Furthermore, liquid biopsy can optimize therapeutic management by overcoming the issue of tumor heterogeneity, monitoring tumor burden, and detecting minimal residual disease (MRD), i.e., the presence of tumor-specific ctDNA, post-operatively. The latter is strongly prognostic and is likely to become a guidance in the postsurgical management. In this review, we present the current evidence on the clinical utility of liquid biopsy in early-stage lung cancer, discuss a selection of key trials, and suggest future applications.
format Online
Article
Text
id pubmed-10216452
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102164522023-05-27 Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications Vandekerckhove, Olivia Cuppens, Kristof Pat, Karin Du Pont, Bert Froyen, Guy Maes, Brigitte Cancers (Basel) Review SIMPLE SUMMARY: Early-stage disease non-small cell lung cancer has better outcomes than advanced disease, but 5-year survival rates can drop to approximately 50% in cases of increased tumor size, local extension, or nodal spread. The use of liquid biopsies to enhance diagnosis, optimize perioperative systemic treatments, and allow early detection of relapse is a possible strategy to reduce this burden. This review aims to present the current evidence on clinical applications of liquid biopsies in early-stage non-small cell lung cancer and highlight opportunities for future applications. ABSTRACT: Lung cancer remains the leading cause of cancer death worldwide, with the majority of cases diagnosed in an advanced stage. Early-stage disease non-small cell lung cancer (NSCLC) has a better outcome, nevertheless the 5-year survival rates drop from 60% for stage IIA to 36% for stage IIIA disease. Early detection and optimized perioperative systemic treatment are frontrunner strategies to reduce this burden. The rapid advancements in molecular diagnostics as well as the growing availability of targeted therapies call for the most efficient detection of actionable biomarkers. Liquid biopsies have already proven their added value in the management of advanced NSCLC but can also optimize patient care in early-stage NSCLC. In addition to having known diagnostic benefits of speed, accessibility, and enhanced biomarker detection compared to tissue biopsy, liquid biopsy could be implemented for screening, diagnostic, and prognostic purposes. Furthermore, liquid biopsy can optimize therapeutic management by overcoming the issue of tumor heterogeneity, monitoring tumor burden, and detecting minimal residual disease (MRD), i.e., the presence of tumor-specific ctDNA, post-operatively. The latter is strongly prognostic and is likely to become a guidance in the postsurgical management. In this review, we present the current evidence on the clinical utility of liquid biopsy in early-stage lung cancer, discuss a selection of key trials, and suggest future applications. MDPI 2023-05-10 /pmc/articles/PMC10216452/ /pubmed/37345038 http://dx.doi.org/10.3390/cancers15102702 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vandekerckhove, Olivia
Cuppens, Kristof
Pat, Karin
Du Pont, Bert
Froyen, Guy
Maes, Brigitte
Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications
title Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications
title_full Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications
title_fullStr Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications
title_full_unstemmed Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications
title_short Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications
title_sort liquid biopsy in early-stage lung cancer: current and future clinical applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216452/
https://www.ncbi.nlm.nih.gov/pubmed/37345038
http://dx.doi.org/10.3390/cancers15102702
work_keys_str_mv AT vandekerckhoveolivia liquidbiopsyinearlystagelungcancercurrentandfutureclinicalapplications
AT cuppenskristof liquidbiopsyinearlystagelungcancercurrentandfutureclinicalapplications
AT patkarin liquidbiopsyinearlystagelungcancercurrentandfutureclinicalapplications
AT dupontbert liquidbiopsyinearlystagelungcancercurrentandfutureclinicalapplications
AT froyenguy liquidbiopsyinearlystagelungcancercurrentandfutureclinicalapplications
AT maesbrigitte liquidbiopsyinearlystagelungcancercurrentandfutureclinicalapplications